Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
| 2 assets: 1 Ph 3, 1 Ph 2 | HB0034Phase 2/3 · Psoriasis | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | HL-1186Phase 2 · Diabetic Peripheral Neuropathic Pain | None on record | — | — | — | — | |
Shanghai JMT-BioPrivate | 4 assets: 2 Ph 3, 2 Ph 2 | BecotatugPhase 3 · Non-Small Cell Lung CancerPartial signal | 26 Mar 2027Becotatug · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 2 | GC101Phase 2 · Non-Small Cell Lung Cancer | 20 Dec 2026GC101 · Phase 1 | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 2 | LW402Phase 3 · Atopic DermatitisPartial signal | Mar 2027LW231 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | MWX205Phase 1 · Atherosclerotic Cardiovascular Disease | None on record | — | — | — | — | |
| 2 assets: 2 Ph 1 | CART-BCMAPhase 1 · Multiple Myeloma | 31 Jan 2027F01 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 2 | U32 CAR-TPhase 1/2 · Acute Myeloid Leukemia | 31 Dec 2027U32 CAR-T · Phase 1/2 | — | — | — | — | |
| 3 assets: 1 Ph 2, 2 Ph 1 | UX-DA003Phase 1/2 · Parkinson's Disease | Dec 2027UX-DA001 · Phase 1 | — | — | — | — | |
| 2 assets: 2 Ph 2 | VGN-R08bPhase 1/2 · Parkinson's Disease | 1 Sep 2027VGN-R08b · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 3 | efsubaglutide alfaPhase 3 · Type 2 DiabetesReliable signal | 30 Apr 2027efsubaglutide alfa · Phase 1 | — | — | — | — | |
| 2 assets: 2 Ph 2 | LipovirtidePhase 2 · HIVPartial signal | None on record | — | — | — | — | |
| 5 assets: 3 Ph 3, 2 Ph 2 | Loncipoetin alfa (NuPIAO)Phase 3 · Chronic Kidney DiseasePartial signal | Dec 2026SSGJ-706 · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | FWD1802Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 1 May 2028FWD1802 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | JY232Phase 1 · Multiple Myeloma | 31 Dec 2028JY232 · Phase 1 | — | — | — | — | |
| 2 assets: 2 Ph 2 | INV-6452Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 4 Feb 2028INV-6452 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | MS-553Phase 1/2 · Chronic Lymphocytic Leukemia | Sep 2028MS-553 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2 · Multiple MyelomaWeak signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | RD01 (PEG-EPO)Phase 2 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — | |
Shenzhen TargetRxPrivate | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | DeulorlatinibPhase 3 · Non-Small Cell Lung Cancer | Feb 2027TGRX-1942 · Phase 1 | — | — | — | — |
SHY TherapeuticsPrivate | 1 asset: 1 Ph 1 | SHY-ONC6Phase 1 · Non-Small Cell Lung Cancer | 15 May 2027SHY-ONC6 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | BC008-1APhase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | Arketamine (PRT042)Phase 2 · Major Depressive Disorder | None on record | — | — | — | — | |
| 1 asset: 1 Ph 1 | SIM0505Phase 1 · Non-Small Cell Lung Cancer | Feb 2028SIM0505 · Phase 1 | — | — | — | — | |
Simcha IL-18, Inc.Private | 1 asset: 1 Ph 2 | VevoctadekinPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Sinotau Pharmaceutical GroupPrivate | 1 asset: 1 Ph 2 | XTR003Phase 2 · Heart Failure | 31 Dec 2026XTR003 · Phase 2 | — | — | — | — |
SinteticaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Siolta TherapeuticsPrivate | 1 asset: 1 Ph 2 | STMC-103HPhase 1/2 · Atopic DermatitisPartial signal | None on record | — | — | — | — |
Sirius TherapeuticsPrivate | 2 assets: 2 Ph 2 | SRSD107Phase 2 · Atherosclerotic Cardiovascular Disease | Dec 2027SRSD107 · Phase 2 | — | — | — | — |
Sirtsei PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | ForvisirvatPhase 2 · Major Depressive DisorderPartial signal | None on record | — | — | — | — |
Solu Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | STX-0712Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026STX-0712 · Phase 1 | — | — | — | — |
Sorrento Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | STI-6129Phase 1/2 · Multiple Myeloma | 31 Dec 2026STI-6129 · Phase 1/2 | — | — | — | — |
Sorriso PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | SOR102Phase 1 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
Sparrow PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | clofutribenPhase 2 · Type 2 DiabetesWeak signal | 31 Dec 2027clofutriben · Phase 2 | — | — | — | — |
Specialised TherapeuticsPrivate | 1 asset: 1 Ph 3 | PlitidepsinPhase 3 · Multiple MyelomaPartial signal | None on record | — | — | — | — |
SpinogenixPrivate | 1 asset: 1 Ph 3 | Tazbentetol (SPG302)Phase 2/3 · Amyotrophic Lateral Sclerosis | 31 Dec 2027Tazbentetol (SPG302) · Phase 2/3 | — | — | — | — |
SQ InnovationPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
STADA ArzneimittelPrivate | 6 assets: 3 approved, 2 Ph 3, 1 other | TrigelPhase 3 · Parkinson's DiseasePartial signal | Mar 2027Budesonide (targeted-release) · Approved | — | — | — | — |
Stelexis BioSciencesPrivate | 1 asset: 1 Ph 2 | EganelisibPhase 2 · Acute Myeloid Leukemia | 15 Dec 2027Eganelisib · Phase 1 | — | — | — | — |
Stemline Therapeutics, Inc.Private | 2 assets: 1 approved, 1 Ph 2 | TagraxofuspPhase 2 · Acute Myeloid LeukemiaWeak signal | Nov 2026Elacestrant · Phase 2 | — | — | — | — |
StendhalPrivate | 1 asset: 1 Ph 3 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Sulfateq B.V.Private | 1 asset: 1 Ph 2 | SUL-238Phase 2 · Parkinson's Disease | None on record | — | — | — | — |
Suninflam Inc.Private | 1 asset: 1 Ph 1 | SIF001Phase 1 · Epilepsy | 15 Jan 2027SIF001 · Phase 1 | — | — | — | — |
Suzhou AlphamabPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signal | Dec 2026Envafolimab · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 2 | LM103Phase 2 · Non-Small Cell Lung Cancer | 31 Dec 2027LM103 · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | GH21Phase 2 · Non-Small Cell Lung CancerWeak signal | 30 Dec 2026GH21 · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | IMV102Phase 1 · Multiple Myeloma | 10 Dec 2027IMV102 · Phase 1 | — | — | — | — | |
Suzhou NeuPharma Co., Ltd.Private | 1 asset: 1 Ph 2 | HLX208Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | BAY 3713372Phase 1/2 · Non-Small Cell Lung Cancer | 18 Jun 2029BAY 3713372 · Phase 1/2 | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 2 | PruvonertinibPhase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
Suzhou Sanegene BioPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | IBI3016Phase 2 · Hypertension | 30 Jan 2027IBI3016 · Phase 1 | — | — | — | — |
Suzhou Siran BiotechnologyPrivate | 2 assets: 2 Ph 1 | SA030Phase 1 · Obesity | 30 Mar 2027SA1211 · Phase 1 | — | — | — | — |
Syndeio BiosciencesPrivate | 2 assets: 2 Ph 2 | ZelquistinelPhase 2 · Major Depressive DisorderPartial signal | Sep 2027Zelquistinel · Phase 2 | — | — | — | — |
SynDevRx, Inc.Private | 1 asset: 1 Ph 2 | EvexomostatPhase 2 · HR+/HER2- Metastatic Breast Cancer | Dec 2026Evexomostat · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 1 | SP-101Phase 1 · Major Depressive Disorder | None on record | — | — | — | — | |
SynthekinePrivate | 1 asset: 1 Ph 2 | STK-012Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2029STK-012 · Phase 1/2 | — | — | — | — |
SystImmunePrivate | 2 assets: 1 Ph 3, 1 Ph 1 | BL-M11D1Phase 2/3 · Acute Myeloid Leukemia | None on record | — | — | — | — |
T's PharmaPrivate | 2 assets: 1 Ph 3, 1 other | VoglibosePhase 3 · Type 2 Diabetes | None on record | — | — | — | — |
T3D TherapeuticsPrivate | 1 asset: 1 Ph 3 | T3D-959Phase 2/3 · Alzheimer's DiseasePartial signal | Apr 2031T3D-959 · Phase 2/3 | — | — | — | — |
Taiho OncologyPrivate | 1 asset: 1 approved | Approved assets only | Dec 2026Decitabine/cedazuridine (Inqovi) · Phase 1 | — | — | — | — |
Taiho PharmaceuticalPrivate | 7 assets: 1 approved, 5 Ph 3, 1 Ph 2 | CasdatifanPhase 3 · Clear Cell Renal Cell Carcinoma | May 2027Casdatifan · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | MitoCellPhase 1 · Parkinson's Disease | 30 Sep 2027MitoCell · Phase 1 | — | — | — | — | |
Tanabe Pharma CorporationPrivate | 12 assets: 7 approved, 4 Ph 3, 1 Ph 2 | TeneligliptinPhase 3 · Type 2 DiabetesReliable signal | Nov 2026Obicetrapib · Phase 3 | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
Tasca TherapeuticsPrivate | 1 asset: 1 Ph 2 | CP-383Phase 1/2 · Non-Small Cell Lung Cancer | 15 Aug 2028CP-383 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record | — | — | — | — | |
TauRx TherapeuticsPrivate | 1 asset: 1 Ph 3 | Hydromethylthionine mesylatePhase 3 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Technoderma MedicinesPrivate | 1 asset: 1 Ph 2 | TDM-180935Phase 2 · Atopic DermatitisPartial signal | None on record | — | — | — | — |
Teligene USPrivate | 1 asset: 1 Ph 2 | SutetinibPhase 2 · Non-Small Cell Lung Cancer | Dec 2027Sutetinib · Phase 2 | — | — | — | — |
Tenacia BiotechnologyPrivate | 1 asset: 1 Ph 3 | RAP-219Phase 3 · EpilepsyWeak signal | Jun 2027RAP-219 · Phase 1 | — | — | — | — |
TerSera Therapeutics LLCPrivate | 2 assets: 2 approved | Approved assets only | 30 Mar 2027Goserelin · Phase 1 | — | — | — | — |
TheracosPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
TherAguixPrivate | 1 asset: 1 Ph 2 | AGuIXPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
TheratechnologiesPrivate | 4 assets: 4 approved | Approved assets only | Dec 2026Donidalorsen · Phase 3 | — | $16MNov 2024 | Ended May 2025 | — |
TheraviaPrivate | 1 asset: 1 approved | Approved assets only | Feb 2028Hydroxyurea (Siklos) · Phase 2 | — | — | — | — |
Therini Bio, Inc.Private | 1 asset: 1 Ph 1 | THN391Phase 1 · Alzheimer's Disease | 31 Mar 2027THN391 · Phase 1 | — | — | — | — |
Thryv TherapeuticsPrivate | 1 asset: 1 Ph 1 | THRV-1268Phase 1 · Heart FailureWeak signal | 30 Jun 2027THRV-1268 · Phase 2/3 | — | — | — | — |
Tianjin Hemay PharmaceuticalPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | MufemilastPhase 3 · Ulcerative ColitisPartial signal | None on record | — | — | — | — |
Tianjin SinoBiotechPrivate | 1 asset: 1 Ph 2 | Human Serum Albumin/interferon alpha2b fusion proteinPhase 1/2 · Chronic Hepatitis B | None on record | — | — | — | — |
Tillotts Pharma AGPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
TILT Biotherapeutics Ltd.Private | 1 asset: 1 Ph 1 | Igrelimogene litadenorepvecPhase 1 · Non-Small Cell Lung Cancer | Nov 2026Igrelimogene litadenorepvec · Phase 1 | — | — | — | — |
Timberlyne TherapeuticsPrivate | 1 asset: 1 Ph 3 | LumrotatugPhase 3 · Multiple MyelomaWeak signal | Mar 2027Lumrotatug · Phase 2 | — | — | — | — |
TJ Biopharma Co., Ltd.Private | 3 assets: 2 Ph 3, 1 Ph 2 | Efmedaglutide alfaPhase 3 · ObesityPartial signal | 5 Aug 2028Uliledlimab · Phase 2/3 | — | — | — | — |
ToLymph Inc.Private | 1 asset: 1 Ph 2 | Paclitaxel (SMS001)Phase 2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Torii PharmaceuticalPrivate | 1 asset: 1 approved | Approved assets only | Aug 2027Tapinarof · Phase 3 | — | — | — | — |
TORL Biotherapeutics, LLCPrivate | 1 asset: 1 Ph 2 | Ixotatug vedotinPhase 2 · Ovarian Cancer | Oct 2027Ixotatug vedotin · Phase 2 | — | — | — | — |
Treadwell Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | OcifisertibPhase 1/2 · Acute Myeloid LeukemiaWeak signal | None on record | — | — | — | — |
TRex BioPrivate | 1 asset: 1 Ph 1 | TRB-061Phase 1 · Atopic Dermatitis | 2 Sep 2027TRB-061 · Phase 1 | — | — | — | — |
TriGemX BioPrivate | 1 asset: 1 Ph 3 | ElismetrepPhase 3 · Migraine | Feb 2027Elismetrep · Phase 3 | — | — | — | — |
Triveni BioPrivate | 1 asset: 1 Ph 2 | TRIV-509Phase 2 · Atopic Dermatitis | None on record | — | — | — | — |
TrueBinding, Inc.Private | 1 asset: 1 Ph 2 | TB006Phase 2 · Parkinson's Disease | 28 Nov 2026TB006 · Phase 2 | — | — | — | — |
TrueLab BiopharmaceuticalPrivate | 1 asset: 1 Ph 1 | TL-003Phase 1 · Ulcerative Colitis | Apr 2027TL-003 · Phase 1 | — | — | — | — |
Tubulis GmbHPrivate | 1 asset: 1 Ph 2 | TUB-030Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Twinpig Biolab, Inc.Private | 1 asset: 1 Ph 2 | TB511Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027TB511 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 2 | TSN1611Phase 1/2 · Non-Small Cell Lung Cancer | 30 Oct 2027TSN1611 · Phase 1/2 | — | — | — | — | |
Umoja BiopharmaPrivate | 1 asset: 1 Ph 1 | UB-VV500Phase 1 · Multiple Myeloma | 31 Dec 2029UB-VV500 · Phase 1 | — | — | — | — |
UNION TherapeuticsPrivate | 1 asset: 1 Ph 2 | orismilastPhase 2 · Atopic DermatitisReliable signal | None on record | — | — | — | — |
| 2 assets: 1 Ph 3, 1 Ph 1 | UBT251Phase 3 · Obesity | Dec 2026UBT251 · Phase 1 | — | — | — | — | |
United BioPharmaPrivate | 1 asset: 1 Ph 3 | SemzuvolimabPhase 3 · HIVWeak signal | None on record | — | — | — | — |
US WorldMeds, LLCPrivate | 2 assets: 1 approved, 1 Ph 2 | letetresgene autoleucelPhase 2 · Myxoid/Round Cell LiposarcomaWeak signal | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.